138 results about "Tartrate" patented technology

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula I below, and the use of that inhibitor for treating a proliferative disease:

The invention relates to an SNCR (selective non-catalytic reduction) denitration synergist, a denitration composition and a denitration method. The SNCR denitration synergist comprises an organic solvent and alkali metal carboxylate, the mass ratio of the organic solvent to the alkali metal carboxylate is (0.1-1): 1, and the organic solvent is selected from one or more of alcohol, ketone, ether and aldehyde. The alkali metal carboxylate is selected from at least one of formate, acetate, citrate, oxalate, ascorbate and tartrate of alkali metal. According to the SNCR denitration synergist, the denitration efficiency can be remarkably improved in a medium and low temperature interval (600-800 DEG C), ammonia escape is reduced, and secondary pollution is reduced.

A novel salt form of Compound (I) represented by the following structural formula, and its corresponding pharmaceutical compositions, are disclosed.Particular single crystalline forms of 1:1 Compound (I) tartrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating cancer in a subject.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula (I) below, and the use of that inhibitor for treating a proliferative disease.

Sterile filtered liquid lactase composition comprising a lactase, preferably a neutral or acidic lactase, an anion selected from malate, tartrate, citrate, gluconate and / or EDTA and a cation selected from sodium and potassium. Preferably, the composition further comprises a polyol. Addition of the said anions to lactase improves filterability by reducing pressure in a filtration system. Preferably the filtration forms part of an in-line filtration system in the production of a dairy product.

This invention relates to a method for preparing the fenelone intermediate 2-cyanoethyl(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid ester, and also relates to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

This invention discloses a method for resolving isomers of methylfenacin ester, comprising: firstly, dissolving methylfenacin ester in a first solvent and adding L-tartaric acid, dissolving until clear; then adjusting the system temperature to 40℃-53℃ and adding L-tartaric acid seed crystals of the target isomer; subsequently, cooling the system to 20℃-30℃, filtering the precipitated product, and obtaining the L-tartaric acid seed crystals of the target isomer as the filter cake; dissociating the L-tartaric acid seed crystals of the target isomer using an alkaline resin, collecting the filtrate, and drying the filtrate to obtain the target isomer of methylfenacin ester. This invention achieves the resolution of isomers of methylfenacin ester by using L-tartaric acid, and through optimization of conditions, achieves a yield of not less than 74.1% and an ee of 91.1% for the target isomer of methylfenacin ester. The resolution method provided by this invention is simple to operate, easy to control, suitable for large-scale production, and meets industrial needs.

Pharmaceutical compositions comprising tartrate salts of medopredane and methods for making the pharmaceutical compositions are provided. The pharmaceutical composition is useful in the treatment of diseases such as L-DOPA induced dyskinesia.

The utility model discloses a cold stable filtering equipment for brewing, include: filter jar, the top end of filter jar is used for the hole of external connection pipe, the bottom of hole is fixedly connected with the telescopic pipe for sealing shell, one side of filter jar is provided with the discharge pipe, and one end of discharge pipe extends to the inside of telescopic pipe for sealing shell through the hole, and one end of discharge pipe located telescopic pipe for sealing shell is fixedly connected with the stretch extension pipe. The utility model discloses through drawing out height control mechanism, utilize control electric push rod to push the chain wheel upward, and the chain wheel moves upward and rolls simultaneously, and make its chain located one end of telescopic pipe for sealing shell upward and pull telescopic pipe for sealing shell and stretch extension pipe synchronous rising simultaneously, promote telescopic pipe for sealing shell and stretch extension pipe rising and folding simultaneously, be favorable to according to the wine body flow rate adjustment draw out height, guarantee after the wine liquid of filtering for many times can have enough time to carry out the reprecipitation time again, guarantee the wine body tartrate can remove completely.

The invention discloses a preparation method of high-purity strontium fluoride powder, and relates to the technical field of inorganic material preparation. The method comprises the following steps: crushing and grinding a strontianite block into powder, calcining at high temperature to obtain a first mixture, adding the first mixture into hydrochloric acid, stirring for a certain time, and filtering to remove insoluble substances to obtain first filtrate; regulating and controlling the pH and temperature of the first filtrate, adding tartrate, reacting for a period of time while stirring, and quickly filtering to obtain a second filtrate; adding a fluorine-containing salt solution into the second filtrate at normal temperature, stirring for a period of time, filtering and collecting insoluble substances; and finally, washing the insoluble substance with absolute ethyl alcohol, and carrying out vacuum drying, crushing and grinding to obtain the high-purity strontium fluoride powder. The method is simple and efficient, the purity of the prepared strontium fluoride powder is larger than 99.9%, and the strontium fluoride powder can be used for manufacturing optical glass, advanced electronic elements and the like.

The application discloses an anti-caking salt product and a preparation method thereof. The anti-caking salt product comprises raw salt and an anti-caking agent, the anti-caking agent is food-grade ferric tartrate, and the addition amount of the anti-caking agent is 0.05-0.106 g / kg of the salt. The core of the anti-caking method of the salt lies in that the food-grade ferric tartrate is used as the main anti-caking agent, the addition amount is 0.05-0.106 g / kg of the salt, the salt is dried at 100 DEG C for 4 hours, then the anti-caking agent is added, and the water vapor transmission rate is less than or equal to 0.5 g / m 2 24h of high-barrier material packaging, while 6 g of quicklime or 2 g of calcium chloride desiccant is added in every 200 g of the salt. The application also controls the Mg 2+ content in the salt to be less than or equal to 0.02%, the KCl content to be less than or equal to 10%, and the particle size to be in the range of 0.45-0.6 mm, so that the salt caking is synergistically inhibited from multiple dimensions. The method has extremely significant anti-caking effect (the caking rate is only 8.7% after 15 days of open storage), is safe and economical, and has a simple process, and can effectively replace or reduce the use of potassium ferrocyanide, and is suitable for large-scale industrial production.

This invention relates to an extraction method for improving the bioavailability of tartrate tylosin. The method includes subjecting tartrate fermentation broth to a single acid-dissolution and alkali-precipitation treatment, followed by static crystallization to obtain crude tartrate. This crude tartrate is then subjected to extraction and back-extraction steps, followed by decolorization and ultrafiltration to obtain refined tartrate. Finally, it is spray-dried to obtain tartrate tylosin. This invention optimizes the extraction process of tartrate tylosin by combining a single acid-dissolution and alkali-precipitation crystallization purification process with extraction and back-extraction processes, effectively improving the bioavailability of tartrate tylosin.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

The invention provides an injection capable of treating various cancerous pains and postoperative pains and a preparation method of the injection, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: filling nitrogen into water for injection at the temperature of 30-60 DEG C, sequentially adding sodium chloride, citric acid and sodium citrate according to a preparation amount, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, then adding butorphanol tartrate according to a preparation amount, and stirring until the butorphanol tartrate is completely dissolved for later use. According to the preparation method of the butorphinol tartrate injection provided by the invention, the technological parameters are accurately controlled, and the reference preparation prescription of the butorphinol tartrate injection does not need to be changed, so that the sterile guarantee level of the butorphinol tartrate injection can be improved, the increase of the impurity content can be effectively controlled, and the good stability of the butorphinol tartrate injection is ensured.

This invention relates to a method for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid, and also to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

The invention belongs to the technical field of nicotine salt, and relates to 6-methylnicotine-tartrate, a single crystal and a preparation method of the 6-methylnicotine-tartrate. The preparation method of the 6-methylnicotine-tartrate comprises the following steps: S11, dissolving L-tartaric acid in ethanol to obtain an L-tartaric acid solution; s12, dropwise adding 6-methylnicotine into the L-tartaric acid solution to obtain a reaction solution, adding the reaction solution into ethyl acetate, stirring, filtering and washing to obtain a reaction product; and S13, drying the reaction product, so as to obtain the 6-methyl nicotine-tartrate. The technical scheme provided by the invention is simple and easy to operate, low in production cost and high in product purity, can reduce the probability of toxic solvent residues in 6-methylnicotine-tartrate, and is suitable for industrial large-scale production.

The application discloses a preparation process of effervescent tablets containing L-carnitine tartrate, which comprises a main unit, wherein a tank body is arranged, a material cylinder is fixedly connected to the top of the tank body and communicates with the tank body, a discharge port is formed in the bottom of the tank body, a baffle is fixed to the inner wall of the bottom of the material cylinder, a plurality of discharge holes are formed in the baffle at equal intervals, a baffle is arranged below the baffle, and a control assembly for controlling the movement of the baffle is arranged on the top of the tank body. When the rectangular plate rotates, the width of the air making port gradually decreases from the weight block to the rectangular plate, so that the air flow rate increases when the air passes through the air making port, the air speed increases, and the heating rod heats the air when the air passes through the air inlet, the annular 'waterfall'-shaped powder raw material can be blown and dried, and the powder raw material is blown and scattered in the space, that is, the powder raw material particles are separated from each other, so that the hot air can more fully dry the powder raw material.

The application provides modified calcium carbonate, a preparation method thereof and a plugging agent containing the same. The modified calcium carbonate is a dicalcium bis-palmitoyl tartrate hydrophobic modified calcium carbonate. The plugging agent comprises the modified calcium carbonate, natural asphalt, high filtration material, degradable fiber and oil.

The present disclosure relates to a pharmaceutically acceptable salt and a crystal form of a fused pyridine ring derivative and a preparation method therefor. Specifically, the present disclosure relates to a choline salt, sodium salt, potassium salt, calcium salt, arginine salt, lysine salt, meglumine salt, ethanolamine salt, hydrosulfate, hydrochloride, tartrate, maleate, citrate, malate, p-toluenesulfonate, and mesylate, and a crystalline form of a compound as represented by formula (I).

The present invention provides a liquid enzyme preparation of an enzyme having excellent activity stability. Stability of enzymatic activity is improved by accommodating a liquid enzyme preparation that includes an enzyme into a container the internal space of which has been replaced by an inert gas, or by adding, to a liquid enzyme preparation containing a protein deamidase, an additive selected from the group consisting of sugar alcohols, glycerin, ethanol, sulfites, lecithins, citrates, polyphosphates, tartrates, phytic acid, metaphosphoric acid, sodium chloride, tocotrienols, methionine, pectins, beet pigment, capsicum pigment, rosemary extract, tocopherols, tea extract, and butylated hydroxyanisole.

The application discloses a kind of compound oral muscarine antipsychotic drug compositions and preparation method thereof, belong to pharmaceutical composition technical field, its technical scheme main point is a kind of compound oral muscarine antipsychotic drug compositions, the pharmaceutical composition is the composition containing two active ingredients, the composition containing two active ingredients is the combination of xanthomelin tartrate microtablet and trospium chloride microtablet, after two active ingredients are made into microtablet respectively, while guaranteeing that product can be released faster, can also increase the time of drug retention in stomach, significantly increase the penetration absorption of drug in body, reduce the fluctuation of blood drug concentration caused by the inconsistent drug release absorption behavior after each administration, so as to better play a role in body, in addition, the technical scheme in the application does not use complex production process, reduces the process development threshold, significantly increases the process reproducibility and stability.

The invention relates to the technical field of cables, and provides a flame-retardant polyethylene cable material for ships and a preparation method of the flame-retardant polyethylene cable material. The flame-retardant polyethylene cable material for ships comprises the following raw materials in parts by weight: 65-75 parts of polyethylene, 15-20 parts of an ethylene-vinyl acetate copolymer, 20-24 parts of a polyolefin elastomer, 10-15 parts of a flame retardant, 5-7 parts of a compatilizer and 2-3 parts of an antioxidant, the flame retardant is composite zinc borate and metal hydroxide; the preparation method of the composite zinc borate comprises the following steps: adding ferric tartrate and ferric citrate into water, adding zinc borate, stirring, concentrating and drying to obtain the composite zinc borate. According to the technical scheme, the problem of poor flame retardance of the polyethylene cable material for the ship in the related technology is solved.

This invention relates to a method for preparing the fenelone intermediate 2-cyanoethyl (4S)-4-(4-cyano-2-methoxyphenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthidine-3-carboxylic acid ester, and also relates to diastereomeric salts (Va), (Vb), (Vc), and / or (Vd). This method is simple to operate, and the diastereomeric salts can be obtained with very high chemical and enantiomeric purity (tartrate ester content <0.05%) through a single dissociation, avoiding the raw material loss and waste problems caused by multiple dissociations. It also has low production costs and meets the requirements of green production.

The application provides an asymmetric preparation process of (S) or (R)-Ugi amine and a tartrate thereof. The chiral Ugi amine can be used for synthesizing a series of chiral phosphine ligands with a ferrocene skeleton structure, and has a wide application in asymmetric hydrogenation reactions. The application obtains the Ugi amine with single optical activity and the tartrate thereof through acetylation, asymmetric reduction hydrogenation, esterification, amination, salification and other steps with ferrocene as raw material. The raw material is cheap and easy to obtain, the reaction condition is mild, the synthesis route is simple, the yield and chiral purity are high, the generation of "three wastes" is small, the application is suitable for industrial production, and the application has great economic value and social benefits.

To provide a crystal of 2 - (4-acetylbenzyl) - 3 - ((4-fluorophenyl) amino) - 577 - trimethyl-7, 8-dihydro-pyrazolo-imidazo [1, 2-a] 2H [4, 3-e] pyrimidin-4 (5H) - one.SOLUTION: Provided is a crystal of an acid addition salt form selected from, for example, succinate form, citrate form, adipate form, tartrate form (e.g., L-tartrate form), malate form, gluconate form (e.g., D-gluconate form), maleate form, fumarate form, aspartate form (e.g., L-aspartate form), hippurate form, sebacate form, glycolate form, galactarate form, benzoate form, pamoate form, oxalate form and malonate form.SELECTED DRAWING: None

The invention discloses a preparation method of cilnipride tartrate, which is characterized in that YT2303S-01 is used as a starting material, an intermediate 1 and an intermediate 2 are prepared in sequence, and finally the preparation of the cilnipride tartrate is completed. The raw materials adopted by the invention are commercially available products, the raw material sources are stable, and large-scale and industrial production can be conveniently carried out.

The invention provides a preparation method of annomeline tartrate crystal form A. Cu-K alpha radiation is used, and an X-ray powder diffraction pattern of the crystal form A expressed by a 2 theta angle has characteristic peaks at 9.4 degrees + / -0.2 degrees, 20.4 degrees + / -0.2 degrees and 23.7 degrees + / -0.2 degrees. The preparation method comprises the following steps: (1) adding annomeline and L-tartaric acid into a first organic solvent, and stirring to obtain a second organic solvent; stirring and heating to obtain a clear solution; (2) adding a second organic solvent into the settled solution in the step (1), slowly cooling to 2-8 DEG C while stirring, and separating out crystals; and (3) filtering and collecting crystals, washing with a second organic solvent, and carrying out vacuum drying to obtain the Nomeline tartrate crystal form A. The first organic solvent is selected from methanol, ethanol, isopropanol, n-butanol, acetone or a combination thereof, and the second organic solvent is selected from methyl tert-butyl ether, an ester solvent, acetonitrile, an alkane solvent or a combination thereof. The preparation method of the xanthomeline tartrate is simple to operate, high in yield and high in purity.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

The invention discloses an acetylisovaleryltylosin tartrate derivative shown in a general formula I or a pharmaceutically acceptable salt thereof, and preparation and anti-infection application thereof. The compound not only can inhibit infection of bacteria, mycoplasma and chlamydia, but also has the effects of inhibiting PRRSV virus replication and reducing virus titer, and can be used for preventing and treating PRRSV in the pig breeding industry and reducing the morbidity and case fatality rate of PRRSV.